Knight Therapeutics (KHTRF) 4.8417 $KHTRF
Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore
Marketwire - Thu Jul 03, 7:38AM CDT
Medicure Inc. ("Medicure" or the "Company"

(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA"

have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest"

in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore"

will be wholly owned operating subsidiaries. Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3 years. The Ownership Interest and certain other rights, including the Option Rights described below, were obtained by Medicure for its lead role in structuring a US$22.5 million, majority interest purchase and financing of Apicore (the "Purchase"

by Signet Healthcare Partners ("Signet"

, Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, and investors affiliated with Sanders Morris Harris Inc. ("Sanders"

(collectively, the "Investors"

.
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
Marketwire - Thu Jul 03, 7:21AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore"

will be wholly owned operating subsidiaries. The purchase arrangement included a secured loan provided by Knight and Sanders Morris Harris Inc., and an equity investment by Signet Healthcare Partners ("Signet"

for an aggregate amount of US$22.5 million. Medicure Inc. ("Medicure"

acquired a minority interest in Apicore and the founding shareholders of Apicore continue to own a significant minority interest in Apicore.
Knight Therapeutics Inc. Invests in Sectoral Asset Management Inc. for Preferred Access to Canadian Product Rights
Marketwire - Thu Jun 26, 7:03AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a letter of agreement with Sectoral Asset Management Inc. ("Sectoral"

to invest USD$13 million into its New Emerging Medical Opportunities Funds II, Ltd. ("NEMO II"

.
Knight Therapeutics Inc. and Origin Biomed Inc. Sign Secured Debt Financing Agreement
Marketwire - Wed Jun 25, 8:32AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement with privately-held Origin Biomed Inc. ("Origin"

, a company dedicated to the worldwide commercialization of the Neuragen(R) and Bionica brands.
Knight Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto
Marketwire - Wed Jun 18, 1:29AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday June 18, 2014 at 11:30 am ET at the Toronto Board of Trade. A copy of the presentation will be available at www.gud-knight.com.
Knight Reports First Quarter 2014 Results
Marketwire - Wed May 28, 7:21AM CDT
Knight Therapeutics Inc. ("Knight"

(TSX: GUD) today reported its financial results for the quarter ended March 31, 2014.